|
|
Blood, 15 April 2008, Vol. 111, No. 8, pp. 3931-3940.
Prepublished online as a Blood First Edition Paper on December 26, 2007; DOI 10.1182/blood-2007-08-107748.
 Previous Article | Next Article 
Submitted August 20, 2007
Accepted December 19, 2007
Ratio of mutant JAK2-V617F to wild type JAK2 determines the MPD phenotypes in transgenic mice
Ralph Tiedt, Hui Hao-Shen, Marta A. Sobas, Renate Looser, Stephan Dirnhofer, Jurg Schwaller, and Radek C Skoda*
Department of Research, Experimental Hematology, University Hospital Basel, Basel, Switzerland
Servicio de Hematologia y Hemoterapia, Hospital Clinico Universitario de Santiago de Compostela, Santiago de Compostela, Spain
Institute of Pathology, University Hospital Basel, Basel, Switzerland
Department of Research, Childhood Leukemia, University Hospital Basel, Basel, Switzerland
* Corresponding author; email: radek.skoda{at}unibas.ch.
An acquired somatic mutation in the JAK2 gene (JAK2-V617F) is present in the majority of patients with myeloproliferative disorders (MPD). Several phenotypic manifestations, i.e. polycythemia vera (PV), essential thrombocythemia (ET) and primary myelofibrosis, can be associated with the same mutation. We generated JAK2-V617F transgenic mice using a human JAK2 gene with the sequences encoding the kinase domain placed in the inverse orientation and flanked by antiparallel loxP sites. Crossing mice of one transgenic line (FF1) with transgenic mice expressing Cre-recombinase under the control of the hematopoiesis specific Vav promoter led to expression of JAK2-V617F that was lower than the endogenous wild type JAK2. These mice developed a phenotype resembling ET with strongly elevated platelet counts and moderate neutrophilia. Induction of the JAK2-V617F transgene with the interferon-inducible MxCre resulted in expression of JAK2-V617F approximately equal to wild type Jak2 and a PV-like phenotype with increased hemoglobin, thrombocytosis and neutrophilia. Higher levels of JAK2-V617F in mouse bone marrow by retroviral transduction caused a PV-like phenotype without thrombocytosis. These data are consistent with the hypothesis that the ratio of mutant to wild type JAK2 is critical for the phenotypic manifestation. A similar correlation was also found in patients with MPD.
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
Related Article in Blood Online:
-
JAK2V617F: you can't have too much
- Ross L. Levine
Blood 2008 111: 3913.
[Full Text]
[PDF]
This article has been cited by other articles:
|
|
|
|
 
I. Plo, M. Nakatake, L. Malivert, J.-P. de Villartay, S. Giraudier, J.-L. Villeval, L. Wiesmuller, and W. Vainchenker
JAK2 stimulates homologous recombination and genetic instability: potential implication in the heterogeneity of myeloproliferative disorders
Blood,
August 15, 2008;
112(4):
1402 - 1412.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. M. Vannucchi and P. Guglielmelli
Molecular pathophysiology of Philadelphia-negative myeloproliferative disorders: beyond JAK2 and MPL mutations
Haematologica,
July 1, 2008;
93(7):
972 - 976.
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Xing, T. H. Wanting, W. Zhao, J. Ma, S. Wang, X. Xu, Q. Li, X. Fu, M. Xu, and Z. J. Zhao
Transgenic expression of JAK2V617F causes myeloproliferative disorders in mice
Blood,
May 15, 2008;
111(10):
5109 - 5117.
[Abstract]
[Full Text]
[PDF]
|
|
|
| |
